When you see a buyout -- like ASPM up 55% on Covidien's $12/share offer, many traders probably think -- I wish I could have known about it.
Actually, I'm not surprised. One of the blogs I follow had a write-up on ASPM about 17 days ago. The author outlined why ASPM was undervalued. He even suggested that ASPM could be a buyout target for a company like COV (the only buyer named in the article). Unfortunately, I passed on the idea.
But at least I'm following the right people.